Expanding Global Medical Supply
Tilray Increases Global Medical Cannabis Production Capacity to Meet Growing International Demand
Tilray Brands announced a major expansion of its cannabis production capacity, raising annual output to approximately 275 metric tonnes from 210 metric tonnes Montreal Gazette. The increase is driven by expanded cultivation at its Quebec facility in Canada and its EU-GMP-certified facility in Portugal, positioning the company to meet surging international demand for medical cannabis.
The Quebec facility is on track to earn EU-GMP certification within the next 12 months Financial Post, giving Tilray access to globally recognized quality standards that unlock European and international markets. This expansion cements the company's position as a leading global cannabis producer.
Production Capacity Jumps 30 Percent to Meet Global Demand
Tilray is boosting total annual production capacity by roughly 31 percent Montreal Gazette. The increase from 210 to 275 metric tonnes reflects the company's bet that international medical cannabis markets are expanding rapidly. Most of the growth comes from ramped-up output in Quebec and Portugal, Tilray's two key cultivation hubs.
The expansion signals Tilray's confidence in global medical cannabis demand Stratford Beacon Herald. Medical cannabis is used to treat pain, nausea, and other conditions in dozens of countries. By doubling production capacity, Tilray aims to capture a larger share of this growing market.
Quebec Facility Nears European Quality Certification
Tilray's Quebec facility is expected to earn EU-GMP certification within 12 months Financial Post. EU-GMP is the European standard for pharmaceutical manufacturing. It ensures that cannabis products meet strict quality, safety, and purity requirements that European regulators demand.
The certification matters because it unlocks European markets Ontario Farmer. Many countries in the EU allow medical cannabis only if it is produced under EU-GMP standards. Once Quebec achieves this certification, Tilray can sell cannabis products across Europe legally and at scale.
Portugal Facility Already Meets European Standards
Tilray's Portugal facility is already EU-GMP certified The Crag and Canyon. Located in Europe, the facility has met strict pharmaceutical standards and can supply EU markets immediately. It serves as the company's bridge into European medical cannabis demand.
The Portugal site is ramping up output along with Quebec Calgary Sun. Combined, the two facilities now support Tilray's goal to become a global medical cannabis leader. The company expects both sites to reach higher production volumes over the coming months.
Global Medical Cannabis Market Accelerating
Tilray is betting on rapid growth in international medical cannabis Goderich Signal Star. Medical cannabis is now legal in more than 50 countries and regions worldwide. Patients, doctors, and governments are increasingly accepting it as a legitimate treatment option.
The expansion shows how fast the market is moving Fort Saskatchewan Record. Two years ago, many companies doubted global demand would justify massive production increases. Today, Tilray is investing heavily to meet orders from Europe, Australia, and other regions. The company's bet reflects a wider shift: medical cannabis is becoming mainstream.
Sentiment
NeutralPublishers
16
Articles
16
Reach
16
